NCT06978114View on ClinicalTrials.gov

A Study of BL-B01D1+PD-1/PD-L1 Monoclonal Antibody in Patients With Advanced Biliary Tract Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

June 10, 2025

Primary Completion Date

May 31, 2027

Study Completion Date

December 31, 2027

Conditions
Advanced Biliary Tract Cancer
Interventions
DRUG

BL-B01D1

Administration by intravenous infusion for a cycle of 3 weeks.

DRUG

Pembrolizumab

Administration by intravenous infusion for a cycle of 3 weeks.

Trial Locations (1)

Unknown

RECRUITING

Zhongshan Hospital Fudan University, Shanghai

All Listed Sponsors
collaborator

Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

INDUSTRY

lead

Sichuan Baili Pharmaceutical Co., Ltd.

INDUSTRY